Desjardins Has Lowered Expectations for Calian Group (TSE:CGY) Stock Price

Calian Group (TSE:CGY) had its target price dropped by research analysts at Desjardins from C$82.00 to C$61.00 in a research note issued to investors on Thursday,BayStreet.CA reports. The firm currently has a “buy” rating on the stock. Desjardins’ price target suggests a potential upside of 58.36% from the company’s previous close. Desjardins also issued estimates for Calian Group’s Q3 2025 earnings at $1.09 EPS, Q4 2025 earnings at $1.21 EPS, FY2025 earnings at $4.11 EPS and FY2026 earnings at $4.81 EPS.

Several other research analysts also recently issued reports on the stock. Royal Bank of Canada lowered their price target on shares of Calian Group from C$60.00 to C$58.00 and set an “outperform” rating for the company in a report on Thursday. CIBC lowered their price target on shares of Calian Group from C$63.00 to C$62.00 in a report on Friday, February 14th. Finally, Canaccord Genuity Group lowered their price target on shares of Calian Group from C$75.00 to C$60.00 and set a “buy” rating for the company in a report on Thursday.

Calian Group Stock Down 1.0%

Shares of CGY opened at C$38.52 on Thursday. Calian Group has a one year low of C$38.20 and a one year high of C$57.55. The company has a market cap of C$457.27 million, a P/E ratio of 41.25, a P/E/G ratio of 2.50 and a beta of 0.88. The company has a debt-to-equity ratio of 39.54, a current ratio of 1.29 and a quick ratio of 1.20. The firm has a 50 day simple moving average of C$44.66 and a two-hundred day simple moving average of C$46.36.

About Calian Group

Calian Group Ltd operates through four segments namely Advanced Technologies, Health, Learning, and Information Technology. It generates maximum revenue from the Health segment. The company serves health, defence, security, aerospace, engineering, AgTech, and IT industries. Its Health segment includes Clinical Services; Nursing Services; Psychological Services and Medical Property Management.